20 Participants NeededMy employer runs this trial

Ibezapolstat for C. difficile Infection

Recruiting at 14 trial locations
DR
Overseen ByDee Rodriguez
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Acurx Pharmaceuticals Inc.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

Single-arm trial to evaluate the safety and efficacy of ACX-362E \[ibezapolstat\] in patients with recurrent C. difficile infection (CDI).

Are You a Good Fit for This Trial?

This trial is for people who have had at least three episodes of C. difficile infection in the past year, including their current episode, with diarrhea and a positive stool test. At least one previous episode must have been treated with vancomycin or fidaxomicin.

Inclusion Criteria

I have had three or more C. difficile infections in the past year.
I have had at least one previous C. diff infection treated with vancomycin or fidaxomicin.
I have diarrhea and tested positive for C. difficile toxins.

What Are the Treatments Tested in This Trial?

Interventions

  • Ibezapolstat

Trial Overview

The study tests ibezapolstat (ACX-362E), an oral antibiotic, to see if it is safe and effective for treating people with recurrent C. difficile infections. All participants receive this medication; there is no comparison group.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: IbezapolstatExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Acurx Pharmaceuticals Inc.

Lead Sponsor

Trials
1
Recruited
50+